AtaiBeckley Inc. Common Stock (ATAI) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with ATAI
Recent news

Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
ATAI

Lilly Builds Neuroscience into a New Long-Term Growth Driver
Lilly Builds Neuroscience into a New Long-Term Growth Driver
ATAI

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
ATAI

Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
ATAI
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 61.81
- MACD 12/26/9
- 0.13
- EMA 9 of MACD
- 0.18
- MACD histogram
- -0.05
- SMA 50
- $6.85
- Price above SMA 50
- EMA 50
- $6.74
- Price above EMA 50
- SMA 200
- $4.72
- Price above SMA 200
- EMA 200
- $5.16
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of September 10, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 9 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
ATAI

Lilly Builds Neuroscience into a New Long-Term Growth Driver
Lilly Builds Neuroscience into a New Long-Term Growth Driver
ATAI

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
ATAI

Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
ATAI

Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.
ATAI

Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower
Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower
ATAI

How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%
How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%
ATAI

ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders
ATAI

Why Did ATAI, PANW, TRV Stocks Surge To 52-Week Highs Last Week?
Why Did ATAI, PANW, TRV Stocks Surge To 52-Week Highs Last Week?
ATAI

The market for psychedelic drugs to treat mental health conditions gets a big buy signal
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
ATAI
News tone: automated (AI) classification of the article's content, not a price prediction.
About AtaiBeckley Inc. Common Stock
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Glenn Short Ph.D. | Chief Scientific Officer | 1970 |
| Dr. Jason Awe Ph.D. | Vice President of Investor Relations | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 61.81
- MACD 12/26/9
- 0.13
- EMA 9 of MACD
- 0.18
- MACD histogram
- -0.05
- SMA 50
- $6.85
- Price above SMA 50
- EMA 50
- $6.74
- Price above EMA 50
- SMA 200
- $4.72
- Price above SMA 200
- EMA 200
- $5.16
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of September 10, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $7.50
- Average
- $7.75
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +16.0 | -29.3 | -30.1 | |||||||||
| 2022 | -30.4 | +4.7 | -12.2 | -19.4 | -13.1 | -0.3 | +5.8 | +26.8 | -24.6 | -11.1 | +4.4 | -20.4 |
| 2023 | -32.8 | -8.7 | +12.4 | +0.5 | -9.6 | +0.0 | +10.6 | -25.4 | -16.2 | -0.8 | -12.6 | +25.9 |
| 2024 | +5.3 | +7.2 | -7.5 | +6.5 | -23.4 | -17.4 | +14.8 | -8.5 | -4.9 | -5.4 | +64.8 | -21.3 |
| 2025 | -3.1 | -7.0 | -9.3 | +21.0 | +57.1 | -12.0 | +51.3 | +9.8 | +15.3 | +12.3 | -27.3 | +6.5 |
| 2026 | -2.8 | -5.5 | -3.8 | +12.4 | +9.4 | +9.3 | +47.1 | +2.2 | +0.1 |



